PSMAcTION: A Phase II/III, Open-label, International, Multicenter, Randomized Study of AAA817 Versus Standard of Care in the Treatment of Adult Participants With PSMA Positive Metastatic Castration-resistant Prostate Cancer Who Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Latest Information Update: 22 Jan 2025
Price :
$35 *
At a glance
- Drugs AAA 817 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms PSMAcTION
- Sponsors Novartis Pharmaceuticals
- 22 Jan 2025 New trial record